Back

Effect of tafamidis on left atrial function in patients with transthyretin amyloid cardiomyopathy

1 September 2024 (14:00 - 14:50)
Organised by: Logo
Congress Presentation Part of: The different faces of cardiac amyloidosis Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Koya Uemura

Kobe (Japan)

9 More presentations in this session

Presentation thumbnail
Sustained paradoxical vasodilation and blood pressure lowering in response to sympathetic stimulation as markers of disease severity and poor survival in primary AL amyloidosis.
Doctor K. Stamatelopoulos (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Changes in the diagnostic landscape of transthyretin amyloid cardiomyopathy (ATTR-CM): a comparison of tests ordered and test Intervals in 2020 Q4 and 2023 Q4
Mr P. Collins (London, GB)
Abstract Slides Video
Presentation thumbnail
Frailty and associated outcomes in patients with transthyretin cardiac amyloidosis
Doctor C. Fumagalli (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Cardiac transthyretin amyloidosis in patients with conduction system disease
Doctor J. Pudich (Ostrava, CZ)
Abstract Slides Video
Presentation thumbnail
ATTR cardiac amyloidosis after lumbar spinal stenosis- a prospective cohort study
Doctor P. Eldhagen (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
The different faces of cardiac amyloidosis

The Event

Event poster

ESC Congress 2024

1 September 2024 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Left atrial function and the risk of new-onset atrial fibrillation in cardiac amyloidosis
25 August 2023
thumbnail
Congress Presentation
Using dapagliflozin to reduce NT-proBNP and improve symptom in transthyretin cardiac amyloidosis - a series of n-of-1 trials pilot study
19 May 2025
thumbnail
Congress Presentation
Distribution and prognostic impact of left and right systolic and diastolic functions in wild-type transthyretin amyloid cardiomyopathy
31 August 2025
thumbnail
Congress Session
Looking beyond heart failure: could it be transthyretin amyloid cardiomyopathy (ATTR-CM)?
22 May 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources